CSL 689

Drug Profile

CSL 689

Alternative Names: CSL-689; rVIIa-FP

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Haemophilia A; Haemophilia B

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Oct 2016 CSL Behring completes a phase-I clinical trial in Haemophilia A and Haemophilia B in Netherlands and Norway (IV) (NCT02470871)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haemophilia-A in Germany (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top